» Articles » PMID: 36978493

Evaluation of Efflux-Mediated Resistance and Biofilm Formation in Virulent Associated with Healthcare Infections

Abstract

is a significant pathogen identified with healthcare-associated infections. The present study evaluates the role of biofilm and efflux pump activities in influencing high-level resistance in virulent strains in clinical infection. Phenotypic resistance in biotyped ( = 147) from diagnosed disease conditions was classified based on multiple antibiotic resistance (MAR) indices and analysed with logistic regression for risk factors. Efflux pump activity, biofilm formation, and virulence factors were analysed for optimal association in infection using receiver operation characteristics (ROC). Age-specificity (OR [CI] = 0.986 [0.946-1.027]), gender (OR [CI] = 1.44 [0.211-9.827]) and infection sources (OR [CI] = 0.860 [0.438-1.688]) were risk variables for multidrug resistance (MDR)- infection ( < 0.05). Biofilm formers caused 48.2% and 18.5% otorrhea and wound infections (95% CI = 0.820-1.032; = 0.001) respectively and more than 30% multidrug resistance (MDR) strains demonstrated high-level efflux pump activity (95% CI = 0.762-1.016; = 0.001), protease (95% CI = 0.112-0.480; = 0.003), lipase (95% CI = 0.143-0.523; = 0.001), and hemolysin (95% CI = 1.109-1.780; = 0.001). Resistance relatedness of more than 80% and 60% to cell wall biosynthesis inhibitors (ceftazidime, ceffproxil, augumentin, ampicillin) and, DNA translational and transcriptional inhibitors (gentamicin, ciprofloxacin, ofloxacin, nitrofurantoin) were observed ( < 0.05). Strong efflux correlation (r = 0.85, = 0.034) with MDR strains, with high predictive performances in efflux pump activity (ROC-AUC 0.78), biofilm formation (ROC-AUC 0.520), and virulence hierarchical-clustering. Combine activities of the expressed efflux pump and biofilm formation in MDR- pose risk to clinical management and infection control.

Citing Articles

Fecal Carriage of Colibactin-Encoding Associated With Colorectal Cancer Among a Student Populace.

Akinduti P, Izevbigie O, Akinduti O, Enwose E, Amoo E Open Forum Infect Dis. 2024; 11(4):ofae106.

PMID: 38560611 PMC: 10981395. DOI: 10.1093/ofid/ofae106.


Antibacterial and Anti-Biofilm Efficacy of Endolysin LysAB1245 against a Panel of Important Pathogens.

Soontarach R, Srimanote P, Voravuthikunchai S, Chusri S Pharmaceuticals (Basel). 2024; 17(2).

PMID: 38399370 PMC: 10893532. DOI: 10.3390/ph17020155.


Impact of Extract on Biofilm Formation for ESBL-: An Model Study.

Abdulkareem A, Alalwani A, Ahmed M, Al-Meani S, Al-Janaby M, Al-Qaysi A Pharmaceuticals (Basel). 2023; 16(10).

PMID: 37895854 PMC: 10609828. DOI: 10.3390/ph16101383.


Design, green synthesis, and quorum sensing quenching potential of novel 2-oxo-pyridines containing a thiophene/furan scaffold and targeting a R gene on .

Ammar Y, Ragab A, Migahed M, Al-Sharbasy S, Salem M, Riad O RSC Adv. 2023; 13(39):27363-27384.

PMID: 37711372 PMC: 10498153. DOI: 10.1039/d3ra04230h.


The Art of War with : Targeting Mex Efflux Pumps Directly to Strategically Enhance Antipseudomonal Drug Efficacy.

Avakh A, Grant G, Cheesman M, Kalkundri T, Hall S Antibiotics (Basel). 2023; 12(8).

PMID: 37627724 PMC: 10451789. DOI: 10.3390/antibiotics12081304.


References
1.
Litwin A, Rojek S, Gozdzik W, Duszynska W . Pseudomonas aeruginosa device associated - healthcare associated infections and its multidrug resistance at intensive care unit of University Hospital: polish, 8.5-year, prospective, single-centre study. BMC Infect Dis. 2021; 21(1):180. PMC: 7885137. DOI: 10.1186/s12879-021-05883-5. View

2.
Angus A, Lee A, Augustin D, Lee E, Evans D, Fleiszig S . Pseudomonas aeruginosa induces membrane blebs in epithelial cells, which are utilized as a niche for intracellular replication and motility. Infect Immun. 2008; 76(5):1992-2001. PMC: 2346716. DOI: 10.1128/IAI.01221-07. View

3.
Ferrand A, Vergalli J, Pages J, Davin-Regli A . An Intertwined Network of Regulation Controls Membrane Permeability Including Drug Influx and Efflux in Enterobacteriaceae. Microorganisms. 2020; 8(6). PMC: 7355843. DOI: 10.3390/microorganisms8060833. View

4.
Ebersole J, Dawson 3rd D, Emecen-Huja P, Nagarajan R, Howard K, Grady M . The periodontal war: microbes and immunity. Periodontol 2000. 2017; 75(1):52-115. DOI: 10.1111/prd.12222. View

5.
Magiorakos A, Srinivasan A, Carey R, Carmeli Y, Falagas M, Giske C . Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2011; 18(3):268-81. DOI: 10.1111/j.1469-0691.2011.03570.x. View